Sun Pharma’s shares gained after the company received approval from the US Food and Drug Administration (USFDA) for its new blue light device, LED BLU-U, used in the treatment of actinic keratoses (AK) — rough, scaly patches on the skin caused by sun damage.
This new model is used together with LEVULAN KERASTICK, a 20% topical solution of aminolevulinic acid HCl, and is meant for treating mild to moderate AK on the face, scalp, and upper limbs.
Read More: Malaysia Teams Up With Banks to Boost Investment in Johor’s Special Economic Zone
While it treats the same condition as the older model, the new LED BLU-U comes with several improvements:
- Takes up less space in clinics
- Has a flexible five-panel design
- Features better LED light arrangement
- Weighs less
- Offers updated functions that can make it more comfortable for patients and easier for doctors to use
The FDA granted this approval through its Real-Time Review Program, which is used for strong and well-prepared submissions. This also shows the good working relationship between Sun Pharma and the FDA.
Also See: GPT Infra Has Delivered 50% Profit Growth in Q4; Stock Has Climbed 4%
Abhay Gandhi, CEO of Sun Pharma North America, said, “We are happy to get FDA approval for the new LED BLU-U and believe it will benefit many people with actinic keratosis. This new model will bring better results while keeping the high standards of safety and effectiveness that people expect from Sun Pharma.”
Sun Pharma is one of the top pharmaceutical companies globally and the largest in India.
In addition to the FDA approval news, the company also reported a strong financial performance:
- Net profit rose by 15.04% to ₹2,903.38 crore in Q3 FY25 compared to the same period last year
- Revenue from operations increased by 10.46% to ₹13,675.46 crore in Q3 FY25
This news highlights Sun Pharma’s commitment to innovation and its strong position in the pharmaceutical industry.
